Chemours CO Schedule 13G passive stakes

Vanguard Capital Management has reported beneficial ownership of 7,903,519 shares, representing 5.26% of the outstanding common stock of The Chemours Company.

Vanguard Portfolio Management reports beneficial ownership of 6.96% of Chemours Co. common stock as of March 31, 2026.

The Vanguard Group reported zero beneficial ownership in Chemours Co/The following an internal realignment that disaggregated its reporting.

Millennium Management and affiliates report reducing their beneficial ownership in The Chemours Company to 5.1%, falling below the 5% threshold as of July 1, 2025.

FMR LLC and Abigail P. Johnson reported a 3.4% beneficial ownership stake in Chemours Co common stock as of June 30, 2025, held for passive investment purposes.

The Vanguard Group has filed an amended Schedule 13G, revealing its beneficial ownership of 11.8% of Chemours Co/The's common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 16.9% beneficial ownership stake in Chemours Company common stock as of June 30, 2025.

Millennium Management LLC, along with its affiliates, has disclosed a passive beneficial ownership of 6.1% of The Chemours Company's common stock.

FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reaffirming their beneficial ownership of 5.1% of Chemours Co. common stock as of May 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 14.2% beneficial ownership stake in Chemours Company as of March 31, 2025, held for passive investment purposes.

FMR LLC and Abigail P. Johnson have jointly filed an amended Schedule 13G, reporting a combined beneficial ownership of 10.2% of Chemours Co.'s common stock as of January 31, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a beneficial ownership of 9.9% of Chemours Co. common stock as of December 31, 2024, indicating a significant passive institutional investment.